INTRODUCTION
The high relapse rate in Acute Myeloid Leukemia "AML" is a significant clinical problem mainly reflects the survival of residual tumor cells after standard therapy. Simultaneous and rapid epigenetic processes such as DNA methylation and histone posttransductional modifications energize tumor cell to stop or slow its proliferation, differentiation or apoptosis. leading to chemotherapy-resistant phenotyped cells. The epigenetic mechanism of drug resistance gives no exception to abnormal methylation. A theme that is prevalent in the resistant cells and that can be overcome by combining HDAC & methyltransferases inhibitors to AML standard chemotherapy. As the most frequent alterations found in acute leukemia Promoter silencing by DNA methylation is an established mechanism to inhibit tumor suppressor genes. This inhibition reflects a state of deacetylated chromatin, a conformational change signal that is dictated by HDACs. Working in harmony to alter the transcriptome profile, DNA methylation & histone acetylation will induce pluripotent resistant phenotype that can be easily reversed targeting these two machineries.
Epigallocatechingallate "EGCG "in green tea" has been proved to inhibit Dnmt1 & reactivate methylation-silenced genes in cultured cancer cells [1, 2] and work with reduced toxicity comparing to nucleoside hypomethylating analogues [3] . As a novel histone acetyltransferase inhibitor "HATi" with global specificity for the majority of HAT enzymes, EGCG showed no activity toward epigenetic enzymes including HDAC and HMTase [4] and it needs to work in concert with a HDACi counterpart to reach the epigenetic state of gene re-activation. Clinical implications of EGCG in treatment of cancer cells of varying origins [5, 6, 7, 8, 9, 10, 11] would in addition represent a pleiotropic impact in favor of better treatment.
Valproic acid (VPA) is a unique HDAC inhibitor that can enhance (MBD2/dMTase), induce DNA demethylation [12] target a number of non-histone proteins, induce differentiation, cell-cycle arrest [13] & apoptosis [14] . Clinical efficacy of VPA has been proved in many earlier trials, in MDS, advanced, poor risk, & refractory AML patients [15, 16] . A forceful attack to DNA methylation & histone acetylation would then be expected if these two drugs were combined with the standard AML chemotherapy. Only if they proved to work in concert and without a robust effect, a better patients prognosis would be expected.
Silencing of the tumor suppressor p15 INK4b gene by hypermethylation is a frequent event in various hematological malignancies especially in AML [17, 18] . It is correlated with Leukemic transformation in nearly all FAB subtypes & can be detected in bone marrow, peripheral blood cells [19] . Quantifying MRD with estrogen receptor A (ERA) and/or p15 INK4b methylation proved to account for a high relapse risk and reduced relapse-free survival. Reactivation of p15
INK4b by "EGCG" was prescribed earlier [1] . HDACIs as well, proved to induce reactivation of p15
INK4b through activation of its deacetylated promoter [20] and restraining the formation of a repressive complex [21] .
Both EGCG and VPA proved to inhibit NF-κB activation [22, 9] [25, 26] .
In the present study, we tested this hypothesis that epigenetic treatment with the combination of VPA & EGCG, parallel to the standard chemotherapy regimen (3+7) would reverse DNA methylation in vivo. Our data have important potential implications on the therapeutic reversal of pathological DNA methylation in acute myeloid leukemia patients.
1-PATIENTS:
This rd arm only. Epidrugs were given starting from day one of chemotherapy to day eight and for two successive THX cycles.
Valproic acid dose used herein was preceded with pilot studies. Doses 10,20,40 mg/kg.bwt were given for two cycles with chemotherapy. LDH & IL-6 were tested as prognostic indicators. 40 mg/kg.bwt dose was chosen. As drug level is considered to be a factor favoring toxicity or G 1 arrest VPA dose was just within therapeutic levels for epilepsy and thus appears clinically acceptable.
Sequential bone marrow aspirates were obtained when possible. Blood samples were withdrawn before & after each treatment cycles "for the first two cycle". All samples were handled, and coded. Laboratory tests were done according to the designed protocol and all data were recorded "each in the relevant report. Patients were followed up for 18 after end of their consolidation therapy " each patient received 2 induction & 3 to 4 consolidation cycles, median of 6 months" INK4b primers were purchased from Sigma (sense & anti-sense 100 pmoles/μl) assayed as described (30) & amplification was performed using PXE 0.2 thermalcycler (Thermo Electron Co.)
MS-PCR for p15
INK4b gene: 5µg of genomic DNA samples were treated with the chemical bisulfite to convert unmethylated cytosines into uracils. Samples were purified using the "EZ Bisulfite DNA Clean-up Kit™" from ZYMO Research (Cat.D5025) & amplified as described [31] . Primers used for p15 unmethylated reaction were: p15 UM were: Sense 5'-TGT GAT GTG TTT GTA TTT TGT GGT T-3' &Antisense 5'-CCA TAC AAT AAC CAA ACA ACC AA-3'. And p15 M: sense 5'-GCG TTCGTATTTTGC GGT T-3' &Antisense 5'-CGT ACA ATA ACC GAA CGA CCG A-3'
.GAPDH, 5'-CGGAGTCAACGGATT TGGTCGTAT-3' & 5'-AGCCTTCTCCATGGTG G TGAAGAC-3'. PCR conditions were as follows: 95°C for 3 min, then 40 cycles at 95°C for 40 s, 60°C for 40 s and 72°C for 40 s, and a final extension of 3 min at 72°C. Then 5-6% PAGE was used for detection as described (30). 3.5. Dnmt1 Activity Assay: This assay is based on methods pre-described [32, 33] using a sensitive, UV-based, enzyme coupled assay. DNA methyltransferase activity was determined in 10 μL of nuclear extracts. the nuclear extracts were incubated for 1.5 or 2 hrs at 37°C with the Substrate 0.66 µM of poly(dI-dC)·poly(dIdC) and 10 µM of S-adenosyl-L-methylmethionine in a total volume of 10 µl of a pH 7.4 buffer, containing 20 mM TrisHCl, 25% glycerol (v/v), 10 mM EDTA, 0.2 mM PMSF, 0.02% DMSO, and 2 mM MgCl2 as a buffer additive ]. Reaction incubated for 2 hrs The reaction was initiated by the addition of nuclear extracts and stopped by mixing with 300 µl of a solution containing 1% SDS, 0.25 mg/ml carrier salmon testes DNA and 1 mg/ml proteinase K & chilling in ice. 6.5 μl of solution (a) containing ADA (15U/1mg; Worthington Biochem.) & S.adenosyl-Lhomosycteine nucleosidase (1U) were buffered in 173.5 μl solution (b) [ 50% glycrol (v/v) , 0.01 mM KH2PO4 PH 6.0 ]. The mixture is pre warmed to R.T., and 180 μl of that mix is added per well, in a final volume of 200 μl per well. We immediately made wells to zero point and began to measure absorbance at 510 nm. For the background control, aliquots of 10 μl acceptor substrate were added to aliquot 10μl SAM MTase Assay Buffer into each background control well. The background control was subtracted from samples and then a curve of protein content against absorbance was plotted representing rate of the enzyme activity. Except of ADA all other chemicals were purchased from Sigma. The sensitivity of the kit was 1 pg/ml of IL-6. Absorbance was read at 450 nm with (BioTek Elx-800, Germany micro-plate reader), and concentration of IL-6 in sera was determined in pg/ml using standard curve.
HDAC Activity

Determination of TNF-α in patients'
sera: This quantifying was done using Human TNF-α ELISA Development Kit (Peprotech, cat # 900-K25). BSA, & ABTS Liquid Substrate Solution were purchased from Sigma Cat # A-7030, & A3219); Where Dulbecco's PBS [10x] was obtained from (Gibco BRL Cat. # 14200-075). Absorbance was read at 405 nm with wavelength correction set at 650 nm. The sensitivity of the kit was within the range of 32-2000pg/ml.
Determination of VEGF& bFGF:
These assays were set as described [34] using Human EG-VEGF ELISA development Kit (Peprotech, Cat. # 900 K-433) for the quantitative measurement of natural h EG-VEGF in a sandwich ELISA format. The sensitivity of the kit was within the range of 16-1000pg/ml. Absorbance was read using the former BioTek ELISA plate reader BioTek at 405 nm with λ correction at 650 nm. bFGF assay was performed using quantitative sandwich enzyme immunoassay technique. 
RESULTS AND DISSCUSSION
Valproic acid (VPA) & green tea extract have been used as well-tolerated drugs with various therapeutic effects [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In this study we combined these two epidrugs as an epigenetic "parallel treatment" protocol with the standard
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AML chemotherapy (3+7). Peripheral blood samples were collected & tested for effect on the DNA methyltransferase1 "Dnmt1" activity. Methylation activity assay was performed as described previously (Section 3.5) to determine the relative levels of activity following our treatment. Lanes (1) in Fig. (1a) Study recorded "for the first time to our knowledge" a slight decrease in Dnmt1 activity in category of 2 nd treatment arm due to VPA treatment which implies that Dnmt1 gene is possibly regulated by histone acetylation mechanism bearing results recorded earlier (37). Yet this effect was absent in samples from patients treated with doses <40 mg/kg/BWT "pilot study". A possible mechanism discussed earlier of docking of EGCG in the catalytic pocket of the enzyme in vitro (1) may stood for inhibition of the enzyme in vivo as in 3 rd arm (VG group) as well. The effect of inhibitors represented in Figure (1b) fig. (4a) shows tendency toward applying the proposed regimen with p ≤ 0.006 in 2 nd arm & p ≤ 0.003 in 3 rd arm. This decrease in IL-6 came accordant to patient prognosis and lower levels were associated with lower percentage of blasts in the peripheral blood & with decrease in the methyltransferase activity" not shown". Results supported evidence of IL-6 cytokine-mediated alteration of methyltransferase gene expression (38, 39, 40) .
TNFα production was proved to accompany myeloid differentiation (41) and vascularity in the bone marrow as well as increased levels of various angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) (42). Fig. (4b) shows collective results of mean values of TNFα, VEGF & bFGF in (pg/ml) after each treatment cycle. Upon detecting TNF-α level represented the highest decrement percent reaching 57 % after 2nd cycles in 3 rd arm that received VPA+ green tea extract with chemotherapy. While in VA group the percent was 44 %, & only 29% in CHX. The output of Angiogenesis-related cytokines in 2 nd & 3 rd arm was reduced by 60 % & 69 % respectively in case of VEGF, comparing to 37 % in CHX group. While bFGF reduced by 48 % & 39 % respectively comparing to 32 % in CHX group. The marked level of VEGF decrease rather than bFGF supposed to be due the relationship between VEGF secretion and VPA (43) which was lesser in case of EGCG integration.
Investigating the proliferation suppressing potential of the applied regimen, we tested samples for NF-κB inhibition. Figure (5a Survival analyses ( fig. 6 ) provided evidences on rehearse of remission endpoint & decreased risk of relapse. Progress-Free Survival (PFS) curve "upper right" shows that third arm of treatment "VG group" had the fastest & highest ratio of complete remission between groups. Disease-Free Survival (DFS) curve "lower right" showed that the fastest relapse was in CHX group, "that relapse delay came consistent with both drawbacks in p15 
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The majority of patients with high levels of p15INK4B methylation in 1 st arm of treatment in remission (12 /18, 67%) experienced shorter time to relapse (mean 285 days) with statistical significance (P = 0.06), whereas patients with PR in 2 nd arm "all had a reversed levels of methylation" had relapsed later (mean, 510 days, P = 0.005). A notable significant difference in relapse-free survival was observed in 3 rd arm (mean, 720 days; P =0.002). Both arms when compared to CHX group are less likely have a shorter time to end event which is relapse.
Cox-regression Curve for covariates [LDH, NF-κB, VEGF, TNFα levels and MRD] showed (P = 0.00641; HR <1 (Exp(b) = 0.3446 with increasing 95% CI of Exp(b) = 0.1608 to 0.7384 ) With 95% confidence, risk of relapse is approximately 1.8, 2.5 times in CHX group than the risk in VA& VG groups respectively. For the considered regression coefficients:
p< .01, with increasing 95% CI of Exp (b) values were in the positive direction.
Putting forward these results, we bring to a close that targeting the DNA methyltransferase1 & histone deacetylation potential using both Valproic acid & Epigallocatechingallate " together as in the prescribed regimen" had reactivated & reversed the methylation of p15
INK4b gene in vivo of AML patients, retained TGF-ß regulatory signal. We suppose that VPA & EGCG managed together to inhibit methylation directly via inhibiting Dnmt1 & HDAC and indirectly by down-regulation of 22, 38) . Also down-regulation of growth factors including IL-6 & TNFα which held back proliferation of AML blasts. Considering the fact that cells arrested in G 1 progress toward differentiation, and finally to apoptosis (47), the effect of TNF-α on downstream events including NF-κB cytoplasmic translocation, shared to decrease expression of target genes as COX2 "bearing in mind the direct effect of VPA & EGCG on COX-2". Reduction of COX-2 mRNA & protein shared to downregulate the release of VEGF, drew back angiogenic potential and progression of cells from G0 to G1 phase which could free the seizing of apoptotic potential within the tumor niche, abate proliferation & angiogenic switches to the malignant epigene.
In our study, we show that the HDAC inhibitor VPA reversed p15 methylation, induced apoptosis, promoted differentiation and improved patient prognosis, all at the same dose (40 mg/kg.bwt) making a dose-dependent effect unlikely. Yet, the net effect was markedly improved when EGCG in green tea extract was introduced, a factor that reflected patients prognostic dissimilarities between the two arms.
Toxicity grading and evaluation of the applied regimen proved absence of any serious side effects which could be relate to valproic acid toxicity "results not shown", regimen already fulfilled our requirements and for this, therapy should not be further intensified. 
CONCLUSION
